Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Kan Chen

Partner

Liwen Chen

Associate

Nan Chen

Principal

David Chu

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Associate

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho Ph.D

Venture Partner

William Hu

Managing Partner

Duane Kuang

Founding Managing Partner

Nisa Leung

Managing Partner

Lisa Li

Investor

Dingzheng Li

Vice President

Jing Liu

Associate

Chang Liu

Associate

Bin Liu

Associate

Biao Lu

Associate

Shuo Mao

Principal

Will Mcconnell

Principal

Mark McDade

Co-Founder and Managing Partner

Gary Rieschel

Founder and Managing Partner

Motao Sun

Associate

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Rachel Wang

Venture Partner

Xin Wang

Investor

James Wang

Venture Partner

Gillian Xu

RMB funds CFO

Kuantai Yeh

Partner

Peter (Ming) Yin

Principal, Cleantech

Janet Yu Ph.D

Partner

Liang Yuyu

Managing Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Managing Partner

Zhiyuan Zhou

Investor

Zhifeng Zhou

Managing Partner

Yiqing Zhu

Associate

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

Past deals in Early Venture Stage

Joes Future Food

Series A in 2023
Developer of artificial meat. The company develops artificial meat and cultured alternative protein products at the cellular level, committing to creating a new solution for future food supply.

Bioyond Tech

Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Deepway

Series A in 2023
Deepway is a manufacturer of smart vehicles focused on providing intelligent driving solutions for the truck freight market. The company specializes in heavy-duty trucks characterized by low wind resistance bodies and advanced intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to benefit from enhanced efficiency through smart freight systems, ultimately improving transportation and logistics operations.

Soda Health

Series A in 2022
Soda Health is a healthcare technology company dedicated to addressing health inequities and promoting a healthier America. The company offers a technology platform designed to help individuals identify, access, and pay for essential resources that support their health and well-being. By providing personalized benefits and streamlining the reimbursement process, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, making healthcare more accessible and affordable.

Deepway

Series A in 2022
Deepway is a manufacturer of smart vehicles focused on providing intelligent driving solutions for the truck freight market. The company specializes in heavy-duty trucks characterized by low wind resistance bodies and advanced intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to benefit from enhanced efficiency through smart freight systems, ultimately improving transportation and logistics operations.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Biotree

Series A in 2022
Shanghai Biotree Biotech Co., Ltd. specializes in the development and application of life science research technologies. Founded in 2013, the company is based in Shanghai, China, and focuses on sample testing, big data analysis, and technical product development within the life sciences sector. It offers a range of professional services tailored to universities, research institutes, hospitals, and enterprises. Biotree is particularly noted for its expertise in metabolomics, providing early detection and analysis services, as well as consulting related to mass spectrometry and metabolic testing. The company has a strong portfolio of patents in metabolomics and continues to innovate in product development and technology within this field. Since its inception, Biotree has demonstrated consistent growth and profitability, establishing itself as a key player in the domestic metabolomics detection and analysis market.

AskGene Pharma

Series A in 2022
AskGene Pharma is a biotechnology firm. It is developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease. It is unlocking the full therapeutic potential of cytokine molecules with their innovative smart kine prodrug platform. It overcomes a number of significant challenges, providing a clear pathway to a range of next-generation cytokine therapies. They provide safer and better medicines for saving patients’ lives. They are equipped with the most advanced R&D facilities.

Houmo.AI

Series A in 2022
Houmo.AI is a semiconductor company that develops an integrated circuit storage technology for AI computing. The company aims to use disruptive technologies to create AI chips with a "ten-fold effect", to meet the huge computing power demand in the era of true artificial intelligence, and to use unlimited computing power to change the world. Houmo.AI was founded by Dr. Wu Qiang in 2020.

Tingsheng Technology

Series A in 2022
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.

GluBio Therapeutics

Series A in 2022
GluBio Pharmaceutical focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Wowjoy Technology

Series A in 2022
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

SilaGene, Inc.

Series A in 2022
SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.

Axera

Series A in 2022
Developer of an artificial intelligence chip designed to focus on the visual field. The company's chip offers good performance with low power consumption, low-latency, and high-integration architecture system, enabling clients to have real-time video analysis on the terminal, good quality video shooting, and real-time multi-camera integration with low cost.

MKSEMI

Series A in 2022
Provider of high precision location technology IC and solutions. The company focuses on developing high performance, low-power, and highly integrated IC and provides solutions in smartphones, wearables, digital health, smart home and general IoT applications.

Gemsouls

Series A in 2021
Gemsouls is an AI technology that powers virtual characters and their interactions with the real world. Headquarterd in Shanghai.

Xinchuangyuan Semiconductor

Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.

SUPERHEXA

Series A in 2021
Superhexa is a hardware company based in Beijing, founded on October 15, 2020, by Xia Yongfeng. It specializes in the development of personal consumer electronics, aiming to integrate technology seamlessly into everyday life. By focusing on innovation, Superhexa seeks to enhance the user experience and adapt to the evolving needs of consumers.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Supermag

Series A in 2021
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.

Cubenergy Technology

Series A in 2021
Shenzhen Cubenergy Technology Co., Ltd. is an energy technology company established in 2015 and based in Shenzhen, China. The company specializes in providing comprehensive energy data operation services and integrating distributed energy storage systems. Cubenergy Technology develops energy management and storage systems that utilize data analysis to optimize system performance and maintain efficiency. By focusing on these advanced technologies, the company aims to enhance energy management solutions for its users.

BUD

Series A in 2021
Founded in 2019 by former Snap engineers, Risa Feng and Shawn Lin, Singapore-headquartered BUD is a leading global metaverse UGC platform encouraging users to create and share 3D interactive experiences with its easy-to-use creation tools. Since its global launch in November 2021, BUD skyrocketed to the list of top 10 social apps in more than 38 countries around the world including North America, Southeast Asia and South America. Millions of 3D content has been created and traded on the platform. BUD has become a digital social hub where millions of people come to create, play and hangout.

Pluslife

Series A in 2021
PlusLife Biotech is devoted to developing revolutionary molecular diagnostic tools and gene treatment programs employing a new generation of gene technology. Founded in 2017 and is based in Guangzhou, China.

Sanegene Bio

Series A in 2021
Sanegene Bio is currently operating in stealth mode.

Wowjoy Technology

Series A in 2021
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

V Light

Series A in 2021
V Light is an interest social app.

InfStones

Series A in 2021
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Hochuen Medical

Series A in 2021
Hochuen Medical, founded in 2015 by Dr. Robin Liu and Eric Zeng, specializes in contract development and manufacturing, focusing on microfluidic chips and biomedical consumables. The company leverages the extensive management experience of its founders, who have over 20 years in the fields of in vitro diagnostics (IVD), microfluidics, and electronics manufacturing. Hochuen Medical produces a range of in vitro diagnostic products, including microfluidic biochips, disposable consumables for IVD, point-of-care testing kits, life science research consumables, gene sequencing chips, and detection cards for animal, plant, and food safety testing. The company is committed to providing clients with high-quality, end-to-end contract manufacturing solutions, drawing on its expertise in research and production management.

MKSEMI

Series A in 2021
Provider of high precision location technology IC and solutions. The company focuses on developing high performance, low-power, and highly integrated IC and provides solutions in smartphones, wearables, digital health, smart home and general IoT applications.

Render

Series A in 2021
Render is a Chinese manufacturer of high-tech medical products and solutions. Render is a Shenzhen-based company that was founded in 2010.

MeetFuture China

Series A in 2021
MeetFuture China is a technology-driven company that supplies automated transmission systems for the pan-semiconductor industry. It provides automation solutions for leading companies in the semiconductor field since 2016 and provided a highly advantageous overall for industrial upgrading and development with independent and controllable core technologies.

Gaugene

Series A in 2021
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

Xizi Education

Series A in 2021
Xizhi Education (Beijing Xizi Education Technology Co., Ltd.) is a leading enterprise in artificial intelligence empowerment education. The headquarters is located in Zhizhi Street, Zhongguancun, which is known as the “China Silicon Valley”. As one of the key incubators of Tsinghua University, from the aspects of policy, capital and talents, it has been strongly supported by Tsinghua's three innovation and entrepreneurship platforms iCenter, Chuang+ and xlab, and won the honor of Zhongguancun High-tech Enterprise.

ZSHK Laboratories

Series A in 2021
ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.

Sincere Edu

Series A in 2021
Sincere Edu is an online financial professional education brand. With CPA exam training as its entry point, it is committed to building a learning and growth platform that can accompany professional financial professionals throughout their careers. Sear Education hopes to truly meet the various needs of students by reconstructing the models and products of the financial professional education market; through the wisdom sharing and the cultivation of the teacher training system

Ventyx Biosciences

Venture Round in 2021
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Medilink-Global

Series A in 2021
MediLink-Global specializes in healthcare benefits management, offering third-party administration solutions to health insurance providers and corporate organizations. The company delivers a variety of services, including online pre-consultation eligibility verification, claims data capture and validation after consultations, and payment processing. Additionally, MediLink-Global facilitates administrative arrangements for financial guarantees and conducts post-admission follow-up, ensuring effective communication regarding any disapproval or non-admissibility of medical diagnoses. Through these comprehensive services, MediLink-Global supports its clients in managing healthcare benefits efficiently.

Medilink Therapeutics

Series A in 2021
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Casela

Series A in 2021
Casela is a chip and semiconductor company

Wholee

Series A in 2021
Wholee is a member-only zero-markup store.

RFoneTech

Series A in 2021
Developer and seller of radio frequency (RF) integrated circuit products. The company focuses on the combination of process development, model development and product design of RF front-end chips and modules, and its RF integrated circuit products are widely used in 5G mobile communications and Internet of Things equipment.

Cornerstone Robotics

Series A in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

Umoja Biopharma

Series A in 2020
Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.

LaNova Medicines

Series A in 2020
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Cool Academy

Series A in 2020
Cool College is a Beijing-based software-as-a-service(SaaS) developer for employee training services.

Korro Bio

Series A in 2020
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Zion Pharma

Series A in 2020
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

HashQuark

Series A in 2020
HashQuark is a provider of staking and blockchain infrastructure services, specializing in the Proof of Stake (PoS) and Delegated Proof of Stake (DPoS) ecosystems. Founded in 2018 and based in Grand Cayman, the company offers a range of services including staking for institutions, individuals, and market professionals, as well as a Staking Cloud that enables token holders to securely store their tokens and earn staking rewards. HashQuark supports all mainstream PoS blockchains and has completed global server deployment, ensuring secure and stable operations for its clients. The company's focus is on providing efficient node management and fostering investment opportunities for both individual and institutional investors within the blockchain space.

Elevation Oncology

Series A in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.

Biren Technology

Series A in 2020
Biren Technology, based in Shanghai, China, specializes in the design and manufacture of intelligent chips and processors tailored for various computing architectures, including GPU and DSA. The company operates in the high-tech sector, focusing on both hardware and software solutions. Its hardware division develops a range of computing solutions that blend versatility with specificity, while its software department is led by experienced industry professionals. The company also conducts frontier research on new intelligent computing systems, emphasizing innovative architectures and advanced compilation technologies. Biren Technology aims to provide integrated solutions for applications such as cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing, enabling clients to utilize domestic chip solutions and achieve significant technological advancements.

Kingsware

Series A in 2020
Kingsware specializes in developing a robotic process automation system. It is committed to building an enterprise-level safe robot management platform. Its product follows the design concept of safe, easy-to-use, powerful, stable, and efficient, and the system can be deployed and controlled in a large-scale, highly integrated enterprise complex environment.

OriginCell

Series A in 2020
Shanghai Origincell Biological Cryo Equipment Co., Ltd. is a biomedical enterprise established in 2014, headquartered in Shanghai, China. The company specializes in immunological cell collection, separation, and storage services. It manufactures biobanking storage devices, including cryogenic freezers and biobank systems. In addition to its storage solutions, Origincell develops tumor immunotherapy solutions, utilizing advanced technologies such as the 10-phage display library and humanized antibody technology. These innovations support medical facilities in their cancer treatment efforts, positioning Origincell as a key player in the intersection of biobanking and cancer therapy.

Alamar Biosciences

Series A in 2020
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Chuhang Tech

Series A in 2020
Nanjing Chuhang Technology Co., Ltd. specializes in the development and production of millimeter-wave radar technology for advanced driver assistance systems (ADAS) and autonomous driving. The company offers a range of products, including 77 GHz angle radars and forward midrange radars, which are utilized in applications such as blind zone detection, automatic parking, emergency braking, adaptive cruise control, forward crossing warning, heartbeat breath detection, gesture recognition, and smart agriculture. Founded in 2018 and headquartered in Nanjing, China, Chuhang Tech has expanded its presence with subsidiaries in several Chinese cities, as well as in Stuttgart, Germany.

CureGenetics

Series A in 2020
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Wuli Planet

Series A in 2020
Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.

Structure Therapeutics

Series A in 2020
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.

Singular Medical

Series A in 2020
Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients.

Berry Oncology

Series A in 2020
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

NVX Clouds Tech

Series A in 2020
NVX Clouds Tech is an artificial intelligence security computing company focused on data privacy protection. It utilizes unique privacy computing technology to fully protect local and cloud data privacy and security through the Cing Weixin privacy cloud computing platform and all-in-one product line. It also provides solutions for the protection of big data security and commercial secrets in finance. The company aims to build a privacy computing platform for big data, separate the ownership, management, and use rights of the data, fully realize the flow of data, and promote the fourth industrial revolution.

Fingo

Series A in 2020
Fingo is an online shopping platform for customers to buy products and share products with their friends. The platform incorporates social business models in Malaysia to connect and create customers. Fingo leverages on major social platforms where every member who signs up will be treated as a VIP and gain access to a wide selection of quality goods and suppliers from Tmall and Taobao, besides opening up new entrepreneurial opportunities via a members-reward system, allowing people get goods at a cheaper price but also earn through membership.

InfStones

Series A in 2020
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

Jasper Therapeutics

Series A in 2020
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.

Jasper Therapeutics

Series A in 2020
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.

SunnyDental

Series A in 2020
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a comprehensive range of dental services aimed at maintaining oral health and enhancing dental structure. The company offers orthodontics, pediatric dentistry, dental implants, prosthodontics, cosmetic dentistry, periodontics, endodontics, and minimally invasive extractions. By providing diagnosis and treatment for various dental issues, including periodontal disease and dental pulp concerns, Sunny Dental ensures high-quality care for its patients. The focus on specialized services reflects the company’s commitment to addressing the diverse needs of dental health across different age groups.

Jasper Therapeutics

Series A in 2019
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.

OriginCell

Series A in 2019
Shanghai Origincell Biological Cryo Equipment Co., Ltd. is a biomedical enterprise established in 2014, headquartered in Shanghai, China. The company specializes in immunological cell collection, separation, and storage services. It manufactures biobanking storage devices, including cryogenic freezers and biobank systems. In addition to its storage solutions, Origincell develops tumor immunotherapy solutions, utilizing advanced technologies such as the 10-phage display library and humanized antibody technology. These innovations support medical facilities in their cancer treatment efforts, positioning Origincell as a key player in the intersection of biobanking and cancer therapy.
Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.

Yuanxin Huibao

Series A in 2019
Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.

Woof

Series A in 2019
Woof is a street fashion community and e-commerce platform for young generations.

Icosavax

Series A in 2019
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.

Casela

Series A in 2019
Casela is a chip and semiconductor company

Platelet BioGenesis

Series A in 2019
Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Yuanxin Huibao

Series A in 2019
Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.

Pulsar Technology

Series A in 2019
Pulsar is a basic software technology service provider, mainly engaged in technology development, technology promotion, technology transfer, technical consulting, and technical services.

ZD Medical

Series A in 2019
ZD Medical is a medical device company that specializes in the development of innovative optical coherence tomography angiography devices. The company focuses on advancing medical imaging technology to assist healthcare professionals in identifying internal patient symptoms. By concentrating on venous medical imaging and optical imaging technology, ZD Medical aims to enhance the capabilities of healthcare providers, ultimately improving patient treatment outcomes.

Nice Tuan

Series A in 2019
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.

Chuhang Tech

Series A in 2019
Nanjing Chuhang Technology Co., Ltd. specializes in the development and production of millimeter-wave radar technology for advanced driver assistance systems (ADAS) and autonomous driving. The company offers a range of products, including 77 GHz angle radars and forward midrange radars, which are utilized in applications such as blind zone detection, automatic parking, emergency braking, adaptive cruise control, forward crossing warning, heartbeat breath detection, gesture recognition, and smart agriculture. Founded in 2018 and headquartered in Nanjing, China, Chuhang Tech has expanded its presence with subsidiaries in several Chinese cities, as well as in Stuttgart, Germany.

Mech-Mind

Series A in 2019
Mech-Mind Robotics Technologies Ltd. designs, develops, and sells hardware and software solutions for logistics industry. The company manufactures smart cameras, such as Mech-Eye Smart Camera, Mech-Eye Broad Smart Camera, and Mech-Eye Pro S Smart Camera for object recognition, depalletizing, assembly, sorting, and locating. Mech-Mind Robotics Technologies Ltd. also develops software solution that allows robotic camera to recognize objects in different shapes and different sizes. In addition, the company also manufactures logistic parcels picking solution for logistic customers. Mech-Mind Robotics Technologies Ltd. was founded in 2016 and is based in Beijing, China with additional office in Munich, Germany and sale office in Shanghai, China.

Talaris Therapeutics

Series A in 2019
Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.

Structure Therapeutics

Series A in 2019
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.

Bomming Vision

Series A in 2019
Zhuhai Bomming Vision Technology is a high-tech company located in Chinese romantic city--Zhuhai. The company is committed to the development and application of machine vision technology. The core technology and management team members have more than 15 years of experience in image acquisition, recognition, algorithm, and machine vision inspection.

52Toys

Series A in 2019
52Toys is an animation and intellectual property operator based in Beijing that focuses on creating a social platform for toy enthusiasts and collectors. The company leverages internet technology to foster a community where users can connect, share their collections, and engage with others who have similar interests in models, figurines, and toys. This platform not only facilitates interaction among collectors but also enhances the overall experience of collecting through community engagement and shared passions.

Gohoo

Series A in 2019
Gohoo is a boutique e-commerce platform that directly links high-quality goods and suppliers channels by integrating the factory supply chain, thereby reducing the brand premium. The current categories focus on beauty, home, food and so on.

LuPu Investment

Series A in 2019
Lupu Investment Management Co., Ltd. is a privately owned investment manager. The firm also manages private equity fund of funds. It was founded in 2013 and is headquartered in Shanghai, China.

Zion Pharma

Series A in 2019
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

WeRide

Series A in 2019
Guangzhou WeRide Technology Co., Ltd. develops autonomous driving technology for level 4 AD cars. The company also develops own AD hardware solution to fit on cars for surround sensor coverage and full spectrum. The company was founded in 2017 and is headquartered in Guangzhou, China.

V Light

Series A in 2019
V Light is an interest social app.

Woof

Series A in 2018
Woof is a street fashion community and e-commerce platform for young generations.

Try Try

Series A in 2018
Try Try is a clothing brand and concept store.

Chaodian

Series A in 2018
Chaodian Culture

Reelsky Data Systems

Series A in 2018
Beijing Reelsky Data Technology Co., Ltd. offers big data analytics, modeling and data application services. The firm is headquartered in Beijing, China.

WeRide

Series A in 2018
Guangzhou WeRide Technology Co., Ltd. develops autonomous driving technology for level 4 AD cars. The company also develops own AD hardware solution to fit on cars for surround sensor coverage and full spectrum. The company was founded in 2017 and is headquartered in Guangzhou, China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.